Valeo Pharma Agreement Supports $30M Annual Revenue Target From Blood Thinner Product Alone

Valeo Pharma is already a successful, revenue generating, small cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market. This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small cap pharma companies. Q3 Highlights: Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter. Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter. Record 9 months revenues at $10.2 million , up 94% In today’s announcement, Valeo Pharma Obtains Listings for Redesca from Two GPO Representing 700 Hospitals and Healthcare Facilities Across Canada. Highlighted by the following; 2 Group Purchasing Organizations listing agreements cover, Redesca™ and Redesca HP™, as well as 3 other Valeo hospital products The 2 multi-year product listings commenced on October 1, 2021 The GPOs together represent more than 700 hospitals and healthcare facilities across 5 provinces including Ontario The agreement above supports $30M annual revenue target From blood thinner product alone! As you can see above, Valeo is hitting on all cylinders with tremendous revenue growth from new great drugs hitting the Canadian markets as we speak. As a result, the company estimates annual revenue of $160M by 2025. Now sit back, relax and watch this powerful interview with Steve Saviuk CEO of Valeo Pharma.